Immunologic Research

Papers
(The H4-Index of Immunologic Research is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine183
Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients167
COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy144
COVID 19: a clue from innate immunity110
The role of Th17 cells in psoriasis60
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity51
Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview39
Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development36
PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy33
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review33
How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative33
Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease33
TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review29
Iodoprophylaxis and thyroid autoimmunity: an update27
Tumor-infiltrating B cell is associated with the control of progression of gastric cancer25
A review on the immune responses against novel emerging coronavirus (SARS-CoV-2)23
Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases22
Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis21
Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab20
The p53 status in rheumatoid arthritis with focus on fibroblast-like synoviocytes20
Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?20
COVID-19 vaccines adverse events: potential molecular mechanisms20
0.045772790908813